{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:54:27Z","timestamp":1790934867845,"version":"4.1.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11606-026-10506-3","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:42:37Z","timestamp":1778179357000},"page":"3909-3912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterizing Disparities in GLP-1 Receptor Agonist Use Among US Adults With and Without Diabetes"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0173-9927","authenticated-orcid":false,"given":"Jasmin","family":"Castrillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cade","family":"Shadbolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Hii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sumithran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9708-5308","authenticated-orcid":false,"given":"Michelle M.","family":"Dowsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"12","key":"10506_CR1","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jama.2024.18219","volume":"332","author":"TA Hegland","year":"2024","unstructured":"Hegland TA, Fang Z, Bucher K. GLP-1 Medication Use for Type 2 Diabetes Has Soared. JAMA. 2024;332(12):952-953. https:\/\/doi.org\/10.1001\/jama.2024.18219.","journal-title":"JAMA."},{"issue":"6","key":"10506_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.7326\/ANNALS-24-02878","volume":"178","author":"C Shadbolt","year":"2025","unstructured":"Shadbolt C, Elkin J, Schilling C, et al. National Trends in Glucagon-Like Peptide-1 Receptor Agonist Use in Adults Without Diabetes, 2018 to 2022. Ann Intern Med. 2025;178(6):896-898. https:\/\/doi.org\/10.7326\/ANNALS-24-02878.","journal-title":"Ann Intern Med."},{"issue":"12","key":"10506_CR3","doi-asserted-by":"publisher","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Essien UR, et al. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum. 2021;2(12):e214182. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.4182.","journal-title":"JAMA Health Forum."},{"issue":"24","key":"10506_CR4","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1001\/jama.2025.4735","volume":"333","author":"C Kim","year":"2025","unstructured":"Kim C, Ross JS, Jastreboff AM, et al. Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US. JAMA. 2025;333(24):2203-2206. https:\/\/doi.org\/10.1001\/jama.2025.4735.","journal-title":"JAMA."},{"issue":"1","key":"10506_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10557-023-07488-3","volume":"39","author":"ND Wong","year":"2025","unstructured":"Wong ND, Karthikeyan H, Fan W. US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events. Cardiovasc Drugs Ther. 2025;39(1):75-84. https:\/\/doi.org\/10.1007\/s10557-023-07488-3.","journal-title":"Cardiovasc Drugs Ther."},{"key":"10506_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.7326\/M22-3051","volume":"176","author":"S Tang","year":"2023","unstructured":"Tang S, Shao H, Ali MK, et al. Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium\u2013Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample. Ann Intern Med. 2023;176:582-583. https:\/\/doi.org\/10.7326\/M22-3051.","journal-title":"Ann Intern Med."},{"key":"10506_CR7","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1007\/s11606-022-07428-1","volume":"37","author":"C Cai","year":"2022","unstructured":"Cai C, Woolhandler S, McCormick D. et al. Racial and Ethnic Inequities in Diabetes Pharmacotherapy: Black and Hispanic Patients Are Less Likely to Receive SGLT2is and GLP1as. J Gen Intern Med. 2022;37:3501\u20133503. https:\/\/doi.org\/10.1007\/s11606-022-07428-1.","journal-title":"J Gen Intern Med."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10506-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10506-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10506-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:02:24Z","timestamp":1790931744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10506-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":7,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10506"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10506-3","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CSch reports receiving grants paid to his institution from the HCF Research Foundation, Medical Research Future Fund, Victorian Cancer Agency, Eli Lilly, Intuitive Foundation, The University of Melbourne, and St Vincent\u2019s Hospital Melbourne Research Endowment Fund. MWH reports receiving honoraria for lecture to Pillars of Dermatology Practice Symposium; receiving travel support provided by Johnson & Johnson to attend Clinical Surgical Immersion in Bruuges, Belgium; receiving travel support provided by Medtronic to attend Clinical Surgical Immersion in Brisbane, Australia; and being a Chairperson for the HOPE fund. PS reports a National Health and Medical Research Council (NHMRC) grant, paid to her institution; reports being a former council member of the Australian and New Zealand Obesity Society (unpaid) and a current member of The Obesity Collective leadership group (unpaid); reports being a co-author on manuscripts with a medical writer provided by Novo Nordisk, Eli Lilly and payment to her institution for participation in advisory and speaking activities from Novo Nordisk, Eli Lilly. PFC reports receiving research support for investigator-initiated studies from Medacta, Eli Lilly, Medibank Private, HCF foundation, National Health, Medical Research Foundation, and Medical Research Future Fund; receiving royalties from Kluwer; receiving consulting fees from DePuy, Surgeon advisory board, Stryker Corporation, Johnson and Johnson, and Medacta; reports being on the Editorial Board for EFORT Reviews and Journal of Clinical Medicine, and reports being an international corresponding editor for JAAOS International. MMD reports receiving research support for investigator-initiated studies, paid to her institution, from the Medical Research Future Fund, the National Health & Medical Research Council, Eli Lilly, Victorian Orthopaedic Foundation, Australian Orthopaedic Association Research Foundation, HCF Foundation, University of Melbourne, St. Vincent\u2019s Hospital Research Foundation, and Arthritis & Osteoporosis Western Australia; reports receiving payment for provision of advice on guideline development for the Royal Australian College of General Practitioners; reports receiving a sitting fee as a member of the Osteoarthritis Clinical Research Group Data & Safety Monitoring Board; and reports being a Board Director of the Australian Orthopaedic Association Research Foundation. CSha reports receiving research support for investigator-initiated studies, paid to his institution, from Eli Lilly, St. Vincent\u2019s Hospital Research Foundation, and Medical Research Future Fund. No other disclosures were reported.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}